GE HealthCare rises after an earnings beat and a higher profit outlook
Earnings results
- EPS beat +11.7%
Actual: $1.34 · Cons.: $1.2 (adjusted diluted EPS)
- Revenue beat +3.0%
Actual: $5.513B · Cons.: $5.35B (GAAP revenue)
- Guidance
Raised FY2026 adjusted EPS to $4.95–$5.05 from $4.80–$5.00.
Earnings and the stock move
GE HealthCare reported third-quarter results on October 28, with revenue and adjusted profit above dated consensus estimates, and raised its full-year adjusted profit outlook. Revenue growth and a 1.8-percentage-point increase in adjusted operating margin supported the earnings improvement. Our analysis: order growth and the durability of pricing and productivity gains are the next tests of whether higher profits can continue; the more favorable tariff impact should not be assumed permanent.
Q3 2026 earnings recap
GE HealthCare rose 7.99% to $76.79 on October 28, 2026 after beating earnings estimates and raising its profit outlook. Higher sales and stronger margins make the forecast more credible.
- The company sells medical scanners, patient monitors and imaging medicines. Revenue rose 7.2% to $5.51 billion, exceeding the $5.35 billion estimate by 3.0%.
- Adjusted EPS, or profit per share excluding specified items, reached $1.34 versus a $1.2 estimate: an 11.7% beat. Reported GAAP profit per share was $1.36.
- Management raised its full-year adjusted profit forecast to $4.95–$5.05 per share from $4.8–$5. The midpoint rose about 2%, extending the significance beyond one strong quarter.
- Adjusted operating margin rose to 16.6% from 14.8%, helped by sales growth, pricing, productivity and a more favorable tariff impact. Inflation remains a cost risk.
- Imaging medicines revenue grew 13%, faster than the main imaging business. Organic orders grew 4%; sustained orders matter because they support future equipment sales.
- The rally clears the late-October range near $70.1–$72.3. Holding that area on a pullback would support the breakout; falling below $70.1 would weaken it.
Watch whether order growth and margins support the higher outlook. Hospital spending delays, inflation and changes in tariffs could pressure sales or profitability.
Financials and technicals
Charts through Oct 27, 2026. The session move above may reflect later news.
Technical setup and risks
The October 28 rally clears the late-October $70.1–$72.3 trading range. A successful retest would support the breakout; a close below $70.1 would weaken it. These are conditional price areas, not guaranteed outcomes.
AI-assisted research with source and calculation checks. Prices may be delayed. Technical charts use the stated completed session, which can precede the quoted intraday move. Educational information; investing involves risk.